Ultragenyx Pharmaceutical Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 revenue reached $136 million, with strong growth across all commercial products and reaffirmed 2026 guidance of $730–$760 million. Two gene therapies are on track for FDA decisions in the second half, and long-term data for GTX-102 in Angelman syndrome remains positive.
-
Strong commercial growth supports a robust pipeline, with pivotal Angelman and gene therapy programs advancing toward key regulatory milestones. Angelman Phase 3 design addresses placebo effect, and gene therapy durability is supported by long-term data. GSDIa and Sanfilippo approvals are expected in the second half of the year.
-
The company is advancing a diverse rare disease pipeline, with near-term regulatory decisions expected for GSD1A and Sanfilippo, and a pivotal Angelman phase III data readout anticipated in the second half of the year. Profitability is targeted for 2027, supported by a broad commercial footprint and robust late-stage programs.
-
Key updates include strong progress in Angelman syndrome trials, with Aspire phase III powered for cognition and MDRI endpoints, and Aurora supporting broader labeling. Setrusumab shows promise for bone disease with accelerated approval in view. Gene therapy programs advance despite regulatory delays, with launches for Sanfilippo and GSDIa prioritized.
-
The company highlighted robust growth in rare disease treatments, with four commercial products and a strong pipeline including gene therapies for Sanfilippo, glycogen storage disease, and Angelman syndrome. Setrusumab showed BMD and pain improvements but missed fracture endpoints, prompting further analysis.
Fiscal Year 2025
-
Delivered 20% revenue growth in 2025, surpassing guidance, with strong commercial execution and expansion across four products. Strategic restructuring aims for profitability by 2027, supported by cost reductions, new launches, and PRV monetization. Regulatory and market risks remain.
-
Upcoming phase 3 data readouts in Osteogenesis Imperfecta and Angelman syndrome are key near-term value drivers, with both programs showing strong confidence in trial design and commercial potential. Gene therapy programs are advancing toward regulatory milestones mid-year.
-
Imminent phase III data for setrusumab in OI could enable a broad label, with strong efficacy seen in prior studies. Gene therapy filings for Sanfilippo and GSDIa are on track, leveraging manufacturing improvements. Multiple launches and a recent monetization deal position the company for a transformative period.
-
Q3 2025 revenue grew 15% year-over-year to $160M, with strong performance across all commercial products and a $400M royalty sale bolstering liquidity. Pivotal data readouts for key late-stage programs are on track, and 2025 revenue guidance of $640M–$670M is reaffirmed.
-
Q2 2025 revenue grew 13% year-over-year to $166M, with strong performance from CRYSVITA and DULJOVI. Pipeline advanced with key milestones: GTX-102 received FDA breakthrough therapy designation and completed Phase III enrollment, while UX143 and DTX-401 remain on track for major data and regulatory events.
-
Revenue growth is driven by four commercial products, with six late-stage pipeline programs and three potential filings this year. Setrusumab for OI and gene therapies for Sanfilippo IIIA and GSD1a are key near-term opportunities, with profitability targeted by 2027.
-
Profitability is targeted for 2027, with multiple near-term product launches and a robust rare disease pipeline. OI and Angelman programs are advancing, with setrusumab expected to be the largest product. Global expansion and efficient operations support growth.
-
Q1 2025 revenue grew 28% year-over-year to $139 million, led by Crysvita's strong international performance and steady growth in Dojolvi and Evkeeza. Multiple late-stage clinical programs advanced, with key regulatory milestones and data readouts expected in 2025.
-
The presentation outlined a robust rare disease pipeline with multiple near-term product launches, highlighted transformative clinical data in OI, Angelman, and Sanfilippo programs, and projected strong revenue growth with a path to profitability by 2027. Strategic focus on efficiency, regulatory expertise, and proactive reimbursement positions the company for continued success.
Fiscal Year 2024
-
2024 revenue grew 29% to $560M, driven by strong Crysvita and Dojolvi performance, with international expansion and new product launches. Guidance for 2025 projects 14–20% revenue growth, with key clinical milestones and regulatory filings expected.
-
Q3 2024 revenue grew 42% year-over-year to $139 million, driven by strong Crysvita and Dojolvi performance and global expansion. Multiple late-stage programs are advancing toward regulatory submissions, with profitability targeted by end of 2026.
-
Q2 2024 saw strong revenue growth and raised guidance, driven by robust product demand and key clinical milestones. Multiple late-stage programs advanced, with two BLA filings and pivotal data readouts expected in the next 12–18 months.
-
The meeting covered board elections, approval of the incentive plan, auditor ratification, and executive compensation, with all proposals passing. A quorum was established, and a Q&A session was held with stakeholders.
-
Strong clinical data and regulatory progress across multiple rare disease programs set the stage for up to three BLA filings and several global launches by 2026. Commercial strategy leverages existing infrastructure, with a focus on urgent, high-value markets and a clear path to profitability.